Recombinant Human GOT1, N-His

Description of Recombinant Human GOT1, N-His

Introduction

Recombinant Human GOT1, N-His is a protein that has been genetically engineered for use in scientific research and potential therapeutic applications. This protein is a variant of the human enzyme Glutamate Oxaloacetate Transaminase 1 (GOT1), which plays a crucial role in the metabolism of amino acids and energy production in cells. In this article, we will explore the structure, activity, and potential applications of Recombinant Human GOT1, N-His.

Structure of Recombinant Human GOT1, N-His

Recombinant Human GOT1, N-His is a 50 kDa protein that consists of 429 amino acids. It is a homodimer, meaning it is composed of two identical subunits, each containing an active site responsible for its enzymatic activity. The structure of this protein has been determined through X-ray crystallography, revealing a three-dimensional shape that is essential for its function.

Activity of this protein

Recombinant Human GOT1, N-His has the same enzymatic activity as the native human GOT1 enzyme. This protein catalyzes the conversion of glutamate and oxaloacetate to alpha-ketoglutarate and aspartate, a crucial step in the process of amino acid metabolism. This reaction is reversible, allowing the protein to also catalyze the conversion of alpha-ketoglutarate and aspartate back to glutamate and oxaloacetate. This activity is essential for maintaining the balance of amino acids and energy production in cells.

Application as a Drug Target

The activity of GOT1 has been linked to various diseases, including cancer, diabetes, and neurological disorders. As a result, Recombinant Human GOT1, N-His has been identified as a potential drug target for these conditions. By targeting the activity of this protein, researchers hope to develop novel treatments that can disrupt the metabolic pathways involved in these diseases.

Cancer

Several studies have shown that GOT1 is overexpressed in various types of cancer, including liver, breast, and lung cancer. This overexpression has been linked to increased tumor growth and resistance to chemotherapy. By targeting the activity of GOT1, researchers hope to inhibit the growth of cancer cells and sensitize them to chemotherapy, making it a promising target for cancer treatment.

Diabetes

GOT1 also plays a significant role in glucose metabolism, making it a potential target for diabetes treatment. Studies have shown that inhibiting the activity of GOT1 can improve glucose tolerance and insulin sensitivity in animal models of diabetes. This suggests that targeting this protein could be a potential therapeutic approach for managing diabetes.

Neurological Disorders

GOT1 has been linked to neurological disorders such as Alzheimer’s disease and Parkinson’s disease. Studies have shown that this protein is involved in the production of neurotransmitters, which are essential for proper brain function. By targeting the activity of GOT1, researchers hope to develop treatments that can restore the balance of neurotransmitters in the brain and potentially slow the progression of these disorders.

Conclusion

In conclusion, Recombinant Human GOT1, N-His is a genetically engineered protein that plays a crucial role in amino acid metabolism. Its structure and activity make it a potential drug target for various diseases, including cancer, diabetes, and neurological disorders. Further research and development of treatments targeting this protein could lead to significant advancements in the field of medicine.